Diagnoses delirium in older patients.

Rules out PE based on clinical criteria.

Predicts in-hospital mortality in patients admitted with COVID-19.

Differentiates patients with HIT from those with other causes of thrombocytopenia.

Calculates reference values for distance walked, as a measure of functional status.

Assesses for degree of shunting and V/Q mismatch.

Diagnoses hypertension in pediatric patients; official guideline of the American Academy of Pediatrics.

Assesses pain in patients with advanced dementia.

Classifies inhalation injury severity based on bronchoscopic findings.

Assesses mental impairment in elderly patients.

Assesses mental impairment in elderly patients.

Predicts need for massive transfusion in trauma patients.

Predicts volume of intracranial hemorrhage from CT measurements.

Estimates the risk of stroke after a suspected transient ischemic attack (TIA).

Predicts survival in alcoholic hepatitis.

Assesses number of lymphocytes and predicts CD4 count.

Frequently used to assess neutropenic fever in chemotherapy patients.

Assesses appropriate response to anemia, frequently in sickle cell patients.

Describes stages of heart failure and provides recommendations for therapy by stage.

Predicts 30-day mortality after elective or emergency cardiac surgery.

Emergency department classification and management tool for adult patients (greater than 18 years old) with suspected or confirmed SARS-CoV-2 (v1.0, updated April 6, 2021).

Calculates PO/IV NAC dosing for acetaminophen overdose (and nomogram to determine toxic 4 hour level).

Diagnoses rheumatoid arthritis (RA) in patients with undifferentiated inflammatory synovitis.

Provides formal diagnostic criteria for gout.

Predicts risk of NSTEMI complications requiring ICU care.

Predicts in-hospital mortality in patients with heart failure (HF).

Risk stratifies for gout vs non-gout arthritis and helps determine which patients benefit most from joint aspiration.

Assesses chest pain patients at 2 hours for risk of cardiac event.

Diagnoses adult ADHD.

Adjusts D-dimer cutoffs by age to help rule out VTE.

Calculates age-adjusted ESR and CRP in adult patients with rheumatoid arthritis.

Determines risk of in-hospital mortality from upper GI bleeding.

Classifies severity of acute kidney injury, similar to RIFLE Criteria.

Determines MCA stroke severity using available CT data.

Predicts survival in HCC patients.

Predicts likelihood of lower extremity cellulitis over other diagnoses.

Rules out PE if no criteria are present; includes SaO2 adjustment for altitude.

Predicts likelihood of appendicitis diagnosis.

Predicts risk of undiagnosed diabetes to determine who should be screened.

Evaluates states of metabolic acidosis.

Stratifies severity of ankylosing spondylitis (AS) using clinical and laboratory data, specifically CRP.

Stratifies severity of ankylosing spondylitis (AS) using clinical and laboratory data, specifically ESR.

Doses antivenom (CroFab only, not Anavip) for pit viper snakebites.

Rules out aortic dissection.

Estimates ICU mortality.

Predicts risk of postoperative nausea and vomiting (PONV).

Assesses neonates 1 and 5 minutes after birth.

Diagnoses appendicitis based on clinical and laboratory findings.

Predicts risk of pulmonary complications after surgery, including respiratory failure.

Interprets ABG.

Classifies health of patients prior to surgery.

Diagnoses axial spondyloarthritis according to Assessment of Spondyloarthritis International Society (ASAS) criteria.

Diagnoses peripheral spondyloarthritis according to Assessment of SpondyloArthritis International Society (ASAS) criteria.

Determines 10-year risk of heart disease or stroke.

Determines 10-year risk of heart disease or stroke and provides statin recommendations.

Determines the likelihood of hepatic fibrosis and cirrhosis in patients with hepatitis C.

Determines likelihood of pediatric patients developing childhood asthma.

Predicts 90-day poor outcome in patients with acute ischemic stroke.

Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis.

Predicts response to therapy in patients with C. diff.

Determines bleeding risk for patients on warfarin.

Determines stroke risk in patients with atrial fibrillation.

Doses atropine for cholinesterase inhibitor toxicity (prescribed drugs, nerve gas, insecticides).

Identifies at-risk drinkers (i.e., binge drinking) who may not be alcohol-dependent.

Estimates risk of developing type 2 diabetes, mainly in Australian patients.

Predicts risk of delirium during hospitalization.

Rules out bacterial meningitis.

Predicts mortality in acute COPD exacerbation.

Predicts risk of advanced fibrosis in NAFLD patients.

Assesses ability to swallow without aspiration after stroke.

Assesses functional independence, generally in stroke patients.

Calculates daily energy expenditure.

Stratifies blast injuries of lower limbs to guide treatment.

Quantifies post-operative pain for children aged 1-7 years.

Quantifies pain in intubated patients.

Provides equivalents between different benzodiazepines.

Provides diagnostic criteria for acute respiratory distress syndrome (ARDS).

Calculates the total body bicarbonate deficit.

Stages chronic lymphocytic leukemia, similar to Rai Staging System.

Predicts mortality risk in pancreatitis with fewer variables than Ranson's.

Predicts likelihood of successful vaginal delivery.

Stratifies primary blast lung injuries into three categories to guide ventilator treatment.

Calculates total blood volume, red blood cell volume, and plasma volume.

Predicts survival in COPD patients.

Calculates fluid balance from sodium concentrations which indicate net 0.9% saline, and free water losses (GI, urine, etc) and gains (IV fluids, PO, etc).

Calculates body mass index and body surface area.

Predicts 30-day risk of PE-related complications in hemodynamically stable patients.

Identifies patients at risk for pressure ulcers.

Calculates rate of distant brain failure after stereotactic radiosurgery for brain metastasis.

Step-wise management approach to COVID-19 patients based on clinical severity as of June 2, 2020.

Classifies unexplained events and replaces the Apparent Life Threatening Events (ALTE) classification.

Classifies stool (correlates with intestinal transit time).

Distinguishes ventricular tachycardia from supraventricular tachycardia.

Predicts likelihood that biochemical thyrotoxicosis is thyroid storm.

Assesses severity of catatonia.

Predicts likelihood of live birth for elective egg freezing in women.

Screens for excessive drinking and alcoholism.

Predicts poor prognosis after out-of-hospital cardiac arrest and guides utility of cardiac catheterization.

Calculates a corrected calcium level for patients with hypoalbuminemia.

Predicts risk of having previously undiagnosed type 2 diabetes.

Clinically clears cervical spine fracture without imaging.

Classifies severity of angina.

Clears head injury without imaging.

Predicts 30-day serious adverse events in patients presenting with syncope.

Stratifies risk of VTE in surgical patients.

Predicts mortality and morbidity after cardiac surgery.

Calculates cardiac output, cardiac index, and stroke volume.

Predicts risk of in-hospital cardiac arrest.

Provides criteria for psoriatic arthritis diagnosis.

Predicts clinically significant head injuries in children.

Estimates severity of overcrowding in community emergency departments.

Estimates probability that pharyngitis is streptococcal, and suggests management course.

Calculates blood flow to the brain.

Calculates stroke risk for patients with atrial fibrillation, possibly better than the CHADS₂ Score.

Estimates stroke risk in patients with atrial fibrillation.

Predicts death, need for neurosurgical intervention or CT abnormality in children with head trauma.

Predicts 10-year survival in patients with multiple comorbidities.

Estimates cirrhosis severity.

Quantifies pain post-operatively in pediatric patients 1-5 years old.

Predicts intracranial traumatic CT findings in patients with minor head trauma.

Predicts operative time of laparoscopic cholecystectomy.

Predicts large vessel occlusion (LVO) and severe stroke in patients with stroke symptoms.

The CIWA-Ar objectifies severity of alcohol withdrawal.

Determines probability of HIV patients developing CKD in the next 5 years, if they take tenofivir or not.

Estimates GFR based on serum creatinine, serum cystatin C, or both.

Predicts mortality in acute-on-chronic liver failure.

Stages dementia, including Alzheimer's, in elderly patients.

Determines severity of rheumatoid arthritis using only clinical data.

Identifies febrile neutropenia patients at low risk of serious complications.

Assists in diagnosing ventilator-associated pneumonia by predicting benefit of pulmonary cultures.

Assess for red-green color blindness.

Screens for suicidal ideation and behavior.

Establishes ability to detect delirium in high risk settings.

Quantifies impact of COPD symptoms on patients' overall health.

Screens for pediatric delirium.

Assesses dysfunctional anxiety associated with the COVID-19 crisis.

Assesses adequacy of response to platelet transfusion.

Corrects the QT interval for heart rate extremes (choose from Bazett, Fridericia, Framingham, or Hodges formulas).

Predicts suitability for discharge in COVID-19 patients.

Predicts risk of critical illness in hospitalized COVID-19 patients.

Quantifies severity of opiate withdrawal.

Calculates CrCl according to the Cockcroft-Gault equation.

Rates critically ill patients’ pain based on clinical observation.

Determines the current severity of Crohn’s disease.

Stratifies bleeding risk after NSTEMI.

Estimates volume of cryoprecipitate recommended for fibrinogen replacement.

Measures frailty to predict survival.

Quantifies burden of disease in elderly patients (comorbidity scale).

Estimates mortality of community-acquired pneumonia to help determine inpatient vs. outpatient treatment.

Assesses severity of CRS in patients on immunotherapy.

Assesses 5 year risk of treatment failure based on clinical factors.

Predicts risk of death by an intimate partner (IP) in a violent intimate relationship.

Predicts likelihood of recurrence of first VTE.

Predicts in-hospital mortality in acute COPD exacerbation.

Predicts probability of undiagnosed HIV infection.

Predicts in-hospital mortality in DKA.

Doses DigiFab in patients with confirmed digoxin poisoning or overdose.

Estimates survival in patients with primary myelofibrosis.

Predicts compliance with opioid treatment for chronic noncancer pain.

Describes severity of rheumatoid arthritis using clinical and laboratory data, specifically CRP.

Describes severity of rheumatoid arthritis using clinical and laboratory data, specifically ESR.

Evaluates MS disease progression based on patient’s ambulatory ability.

Estimates volume of whole blood to process by apheresis to yield an appropriate DLI dosage.

Predicts 3 month outcome in ischemic stroke patients receiving TPA.

Predicts risk for community-acquired pneumonia due to drug-resistant pathogens.

Diagnoses major depressive disorder (MDD).

Diagnoses posttraumatic stress disorder (PTSD).

Determines 1-year mortality in IPF patients using PFT and clinical indicators.

Predicts which patients will benefit from prolonged DAPT after coronary stent placement.

Estimates functional capacity.

Diagnostic criteria for endocarditis.

Diagnoses and prognoses suspected CAD based on the treadmill exercise test.

Diagnoses familial hypercholesterolemia (FH) based on clinical, genetic and family history.

Predicts overall survival in AML patients with relapsed/refractory disease undergoing myeloablative transplant.

Determines ability of patient to tolerate therapies in serious illness, specifically for chemotherapy, simpler than the Karnofsky Scale.

Predicts likelihood that syncope is from cardiac cause.

Predicts risk of difficult airway.

Diagnoses embolic stroke of undetermined source.

Identifies chest pain patients with low risk of major adverse cardiac event.

Estimates 7-day mortality of emergency CHF patients.

Estimates depth of optimal ETT placement and target tidal volume by height.

Estimates an average glucose level from Hemoglobin A1C value.

Predicts ethanol concentration based on ingestion of alcohol.

Quantifies asthma exacerbation severity.

Predicts risk of in-hospital mortality after major cardiac surgery.

Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase treatments.

Predicts presence and size of esophageal varices before screening endoscopy.

Describes severity of disability in patients with MS.

Diagnoses fatty liver using labs and exam findings.

Predicts need for urgent delivery based on sonographic and nonstress testing.

Predicts likelihood of strep throat.

Noninvasive estimate of liver scarring in HCV and HBV patients, to assess need for biopsy.

Stages cancer of the ovary, fallopian tube, and peritoneum.

Identifies patients at high risk for type 2 diabetes.

Rates risk of vasospasm in aSAH based on amount and distribution of blood on CT.

Provides guidelines for management of solid and subsolid pulmonary nodules.

Predicts presence of pericardial or intra-abdominal injury after penetrating or blunt trauma.

Estimates overall survival based on clinical information.

Doses fomepizole for methanol and ethylene glycol reversal.

Predicts recurrence for colorectal cancer patients with liver metastasis after hepatic resection.

For use by non-clinicians. Calculate your or a loved one's risk of dying within 30 days of contracting COVID-19. See risk visualization in results for more info.

Stratifies severity of upper GI bleeding according to endoscopic findings.

Grades coma severity; may be more accurate than the Glasgow Coma Scale.

Determines if renal failure is due to pre-renal, intrinsic, or post-renal pathology.

Determines the cause of renal failure. Similar to the FENa, but can be used on patients on diuretics.

Diagnoses heart failure based on major and minor criteria.

Estimates 10-year risk of heart attack.

Calculates free water deficit by estimated total body water.

Provides prognostic grading system for tumor cells based on physical cellular appearance.